A storied Chinese pharma partner of Bristol Myers, Amgen — and avid biotech supporter — plots HK IPO
A hefty pharma IPO is coming to Hong Kong.
Simcere isn’t one of the group of pre-revenue biotechs taking advantage of Hong Kong’s 2-year-old new rules that opened up the stock exchange. A closer counterpart would be Hansoh, which reaped a $1 billion windfall from its HKEX debut a year ago: a storied powerhouse company that bags sizable revenue from a slate of older generic drugs. (Coincidentally, both companies have headquarters in the province of Jiangsu.)
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.